

Sub
Conclude and the step of reactivating and re-stimulating is initiated when T cell size has decreased or when the level of the cell surface molecule has decreased.

59. The method of claim 58, wherein the cell surface molecule is B7-1.

REMARKS


Claims 1-49 were pending in the present application. Claims 2-49 have been cancelled without prejudice and new claims 50-59 have been added. Accordingly, claims 1 and 50-59 are currently pending. Support for the new claims can be found throughout the specification, including the originally filed claims.

No new matter has been added. Any amendments to and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite the prosecution of the application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

CONCLUSION

In view of the amendments and remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Amy E. Mandragouras

Reg. No. 36,207

Attorney for Applicants

28 State Street
Boston, Massachusetts 02109
telephone: (617) 227-7400
facsimile: (617) 742-4214
Date: 7/8/99